Literature DB >> 31701087

Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution.

Joel T Haas1, Luisa Vonghia2,3, Denis A Mogilenko1, An Verrijken3,4, Olivier Molendi-Coste1, Sébastien Fleury1, Audrey Deprince1, Artemii Nikitin1, Eloïse Woitrain1, Lucie Ducrocq-Geoffroy1, Samuel Pic1, Bruno Derudas1, Hélène Dehondt1, Céline Gheeraert1, Luc Van Gaal3,4, Ann Driessen5, Philippe Lefebvre1, Bart Staels1, Sven Francque2,3, David Dombrowicz1.   

Abstract

Progression of fatty liver to non-alcoholic steatohepatitis (NASH) is a rapidly growing health problem. Presence of inflammatory infiltrates in the liver and hepatocyte damage distinguish NASH from simple steatosis. However, the underlying molecular mechanisms involved in the development of NASH remain to be fully understood. Here we perform transcriptional and immune profiling of NASH patients before and after lifestyle intervention (LSI). Analysis of liver microarray data from a cohort of patients with histologically assessed NAFLD reveals a hepatic gene signature, which is associated with NASH and is sensitive to regression of NASH activity upon LSI independently of body weight loss. Enrichment analysis reveals the presence of immune-associated genes linked to inflammatory responses, antigen presentation and cytotoxic cells in the NASH-linked gene signature. In an independent cohort, NASH is also associated with alterations in blood immune cell populations, including conventional dendritic cells (cDC) type 1 and 2, and cytotoxic CD8 T cells. Lobular inflammation and ballooning are associated with the accumulation of CD8 T cells in the liver. Progression from simple steatosis to NASH in a mouse model of diet-driven NASH results in a comparable immune-related hepatic expression signature and the accumulation of intra-hepatic cDC and CD8 T cells. These results show that NASH, compared to normal liver or simple steatosis, is associated with a distinct hepatic immune-related gene signature, elevated hepatic CD8 T cells, and altered antigen-presenting and cytotoxic cells in blood. These findings expand our understanding of NASH and may identify potential targets for NASH therapy.

Entities:  

Mesh:

Year:  2019        PMID: 31701087      PMCID: PMC6837876          DOI: 10.1038/s42255-019-0076-1

Source DB:  PubMed          Journal:  Nat Metab        ISSN: 2522-5812


  53 in total

1.  Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists.

Authors:  David E Kleiner; Pierre Bedossa
Journal:  Gastroenterology       Date:  2015-09-25       Impact factor: 22.682

2.  HLA DQB1 alleles are related with nonalcoholic fatty liver disease.

Authors:  Levent Doganay; Seyma Katrinli; Yasar Colak; Ebubekir Senates; Ebru Zemheri; Oguzhan Ozturk; Feruze Yilmaz Enc; Ilyas Tuncer; Gizem Dinler Doganay
Journal:  Mol Biol Rep       Date:  2014-08-26       Impact factor: 2.316

Review 3.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

4.  Adipose type I interferon signalling protects against metabolic dysfunction.

Authors:  Verena Wieser; Timon Erik Adolph; Christoph Grander; Felix Grabherr; Barbara Enrich; Patrizia Moser; Alexander Rupert Moschen; Susanne Kaser; Herbert Tilg
Journal:  Gut       Date:  2016-12-23       Impact factor: 23.059

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice.

Authors:  Justin R Henning; Christopher S Graffeo; Adeel Rehman; Nina C Fallon; Constantinos P Zambirinis; Atsuo Ochi; Rocky Barilla; Mohsin Jamal; Michael Deutsch; Stephanie Greco; Melvin Ego-Osuala; Usama Bin-Saeed; Raghavendra S Rao; Sana Badar; Juan P Quesada; Devrim Acehan; George Miller
Journal:  Hepatology       Date:  2013-06-24       Impact factor: 17.425

7.  Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces.

Authors:  Yuri P Rubtsov; Jeffrey P Rasmussen; Emil Y Chi; Jason Fontenot; Luca Castelli; Xin Ye; Piper Treuting; Lisa Siewe; Axel Roers; William R Henderson; Werner Muller; Alexander Y Rudensky
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

8.  Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin.

Authors:  Philippe Lefebvre; Fanny Lalloyer; Eric Baugé; Michal Pawlak; Céline Gheeraert; Hélène Dehondt; Jonathan Vanhoutte; Eloise Woitrain; Nathalie Hennuyer; Claire Mazuy; Marie Bobowski-Gérard; Francesco Paolo Zummo; Bruno Derudas; Ann Driessen; Guy Hubens; Luisa Vonghia; Wilhelmus J Kwanten; Peter Michielsen; Thomas Vanwolleghem; Jérôme Eeckhoute; An Verrijken; Luc Van Gaal; Sven Francque; Bart Staels
Journal:  JCI Insight       Date:  2017-07-06

9.  Human hepatic gene expression signature of non-alcoholic fatty liver disease progression, a meta-analysis.

Authors:  Maria Ryaboshapkina; Mårten Hammar
Journal:  Sci Rep       Date:  2017-09-27       Impact factor: 4.379

Review 10.  Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis.

Authors:  Luisa Vonghia; Peter Michielsen; Sven Francque
Journal:  Int J Mol Sci       Date:  2013-10-01       Impact factor: 5.923

View more
  43 in total

1.  Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches.

Authors:  Martin Guilliams; Johnny Bonnardel; Birthe Haest; Bart Vanderborght; Camille Wagner; Anneleen Remmerie; Anna Bujko; Liesbet Martens; Tinne Thoné; Robin Browaeys; Federico F De Ponti; Bavo Vanneste; Christian Zwicker; Freya R Svedberg; Tineke Vanhalewyn; Amanda Gonçalves; Saskia Lippens; Bert Devriendt; Eric Cox; Giuliano Ferrero; Valerie Wittamer; Andy Willaert; Suzanne J F Kaptein; Johan Neyts; Kai Dallmeier; Peter Geldhof; Stijn Casaert; Bart Deplancke; Peter Ten Dijke; Anne Hoorens; Aude Vanlander; Frederik Berrevoet; Yves Van Nieuwenhove; Yvan Saeys; Wouter Saelens; Hans Van Vlierberghe; Lindsey Devisscher; Charlotte L Scott
Journal:  Cell       Date:  2022-01-11       Impact factor: 41.582

Review 2.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

Review 3.  Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease.

Authors:  Philippe Lefebvre; Bart Staels
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

4.  Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.

Authors:  Naoto Fujiwara; Naoto Kubota; Emilie Crouchet; Bhuvaneswari Koneru; Cesia A Marquez; Arun K Jajoriya; Gayatri Panda; Tongqi Qian; Shijia Zhu; Nicolas Goossens; Xiaochen Wang; Shuang Liang; Zhenyu Zhong; Sara Lewis; Bachir Taouli; Myron E Schwartz; Maria Isabel Fiel; Amit G Singal; Jorge A Marrero; Austin J Fobar; Neehar D Parikh; Indu Raman; Quan-Zhen Li; Masataka Taguri; Atsushi Ono; Hiroshi Aikata; Takashi Nakahara; Hayato Nakagawa; Yuki Matsushita; Ryosuke Tateishi; Kazuhiko Koike; Masahiro Kobayashi; Takaaki Higashi; Shigeki Nakagawa; Yo-Ichi Yamashita; Toru Beppu; Hideo Baba; Hiromitsu Kumada; Kazuaki Chayama; Thomas F Baumert; Yujin Hoshida
Journal:  Sci Transl Med       Date:  2022-06-22       Impact factor: 19.319

Review 5.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

Review 6.  Understanding the cellular interactome of non-alcoholic fatty liver disease.

Authors:  Sebastian J Wallace; Frank Tacke; Robert F Schwabe; Neil C Henderson
Journal:  JHEP Rep       Date:  2022-06-15

7.  Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

Authors:  Tamara Vanhaecke; Robim M Rodrigues; Joost Boeckmans; Alessandra Natale; Matthias Rombaut; Karolien Buyl; Brent Cami; Veerle De Boe; Anja Heymans; Vera Rogiers; Joery De Kock
Journal:  Cell Biol Toxicol       Date:  2020-07-01       Impact factor: 6.691

8.  XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis.

Authors:  Assaf Weiner; Ziv Ben-Ari; Mathias Heikenwälder; Eran Elinav; Ido Amit; Aleksandra Deczkowska; Eyal David; Pierluigi Ramadori; Dominik Pfister; Michal Safran; Baoguo Li; Amir Giladi; Diego Adhemar Jaitin; Oren Barboy; Merav Cohen; Ido Yofe; Chamutal Gur; Shir Shlomi-Loubaton; Sandrine Henri; Yousuf Suhail; Mengjie Qiu; Shing Kam; Hila Hermon; Eylon Lahat; Gil Ben Yakov; Oranit Cohen-Ezra; Yana Davidov; Mariya Likhter; David Goitein; Susanne Roth; Achim Weber; Bernard Malissen
Journal:  Nat Med       Date:  2021-05-20       Impact factor: 53.440

Review 9.  Infections at the nexus of metabolic-associated fatty liver disease.

Authors:  Robim M Rodrigues; Tamara Vanhaecke; Joost Boeckmans; Matthias Rombaut; Thomas Demuyser; Baptist Declerck; Denis Piérard; Vera Rogiers; Joery De Kock; Luc Waumans; Koen Magerman; Reinoud Cartuyvels; Jean-Luc Rummens
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

10.  CD8+ tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells.

Authors:  Yuzo Koda; Toshiaki Teratani; Po-Sung Chu; Yuya Hagihara; Yohei Mikami; Yosuke Harada; Hanako Tsujikawa; Kentaro Miyamoto; Takahiro Suzuki; Nobuhito Taniki; Tomohisa Sujino; Michiie Sakamoto; Takanori Kanai; Nobuhiro Nakamoto
Journal:  Nat Commun       Date:  2021-07-22       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.